A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+metastatic breast cancer

被引：17
|
作者：
LoRusso, Patricia [1 ]
Krop, Ian [2 ]
Miller, Kathy [3 ]
Ma, Cynthia [4 ]
Siegel, Barry A. [4 ]
Shields, Anthony F. [5 ]
Molnar, Istvan [6 ]
Wickham, Thomas [6 ]
Reynolds, Joseph [6 ]
Campbell, Karen [6 ]
Hendriks, Bart [6 ]
McClure, Ty [6 ]
Moyo, Victor [6 ]
Munster, Pamela [7 ]
机构：
[1] Yale, New Haven, CT USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Indiana Univ, Indianapolis, IN 46204 USA
[4] Washington Univ, St Louis, MO USA
[5] Karmanos, Detroit, MI USA
[6] Merrimack Pharmaceut, Cambridge, MA USA
[7] UCSF, San Francisco, CA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-CT234
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT234
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Phase I Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2-Positive Breast Cancer
    Wickham, T.
    Futch, K.
    CANCER RESEARCH, 2012, 72
  • [2] A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer
    Munster, Pamela N.
    Miller, Kathy
    Krop, Ian E.
    Dhindsa, Navreet
    Reynolds, Joe
    Geretti, Elena
    Niyikiza, Clet
    Nielsen, Ulrik
    Hendriks, Bart
    Wickham, Thomas J.
    Moyo, Victor M.
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer
    Munster, P.
    Krop, I. E.
    Miller, K.
    Dhindsa, N.
    Niyijiza, C.
    Nielsen, U.
    Odueyungbo, A.
    Rajarethinam, A.
    Marande, M.
    Campbell, K.
    Geretti, E.
    Reynolds, J. G.
    Hendriks, B. S.
    Wickham, T.
    Moyo, V.
    LoRusso, P.
    CANCER RESEARCH, 2013, 73
  • [4] HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo
    Geretti, Elena
    Espelin, Christopher
    Adiwijaya, Bambang
    Dumont, Nancy
    Coma, Silvia
    Koncki, Zachary
    Minh Pham
    Garcia, Gabriela
    Bloom, Troy
    Rimkunas, Victoria
    Reynolds, Joe
    Campbell, Karen
    Moyo, Victor
    Molnar, Istvan
    LoRusso, Patricia
    Krop, Ian
    Miller, Kathy
    Ma, Cynthia
    Munster, Pamela
    Wickham, Thomas
    CANCER RESEARCH, 2016, 76
  • [5] MM-302, HER2-targeted liposomal doxorubicin, does not impair cardiomyocyte function in vitro
    Reynolds, Joseph
    Klinz, Stephan
    Leonard, Shannon
    Geretti, Elena
    Lee, Helen
    Eckelhofer, Isabelle
    Gaddy, Daniel
    Hendriks, Bart
    Wickham, Tom
    CANCER RESEARCH, 2011, 71
  • [6] Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
    Pamela Munster
    Ian E. Krop
    Patricia LoRusso
    Cynthia Ma
    Barry A. Siegel
    Anthony F. Shields
    István Molnár
    Thomas J. Wickham
    Joseph Reynolds
    Karen Campbell
    Bart S. Hendriks
    Bambang S. Adiwijaya
    Elena Geretti
    Victor Moyo
    Kathy D. Miller
    British Journal of Cancer, 2018, 119 : 1086 - 1093
  • [7] Effect of pre-treatment with cyclophosphamide on MM-302 (HER2-targeted liposomal doxorubicin) deposition in HER2-positive metastatic breast cancer patients assessed by 64Cu-MM-302 PET/CT
    Miller, Kathy
    LoRusso, Patricia M.
    Munster, Pamela
    Krop, Ian
    Ma, Cynthia
    Lee, Helen
    Reynolds, Joe
    Campbell, Karen
    Moyo, Victor
    Hendriks, Bart
    Wickham, Thomas
    Siegel, Barry A.
    Shields, Anthony F.
    CANCER RESEARCH, 2015, 75
  • [8] Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
    Munster, Pamela
    Krop, Ian E.
    LoRusso, Patricia
    Ma, Cynthia
    Siegel, Barry A.
    Shields, Anthony F.
    Molnar, Istvan
    Wickham, Thomas J.
    Reynolds, Joseph
    Campbell, Karen
    Hendriks, Bart S.
    Adiwijaya, Bambang S.
    Geretti, Elena
    Moyo, Victor
    Miller, Kathy D.
    BRITISH JOURNAL OF CANCER, 2018, 119 (09) : 1086 - 1093
  • [9] OPTIMIZING DELIVERY OF HER2-TARGETED LIPOSOMAL DOXORUBICIN (MM-302) THROUGH IMAGING, COMPUTATIONAL ANALYSES AND EXPERIMENTATION
    Hendriks, Bart
    DRUG METABOLISM REVIEWS, 2014, 45 : 16 - 16
  • [10] In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors
    Geretti, E.
    Espelin, C.
    Adiwijaya, B.
    Coma, S.
    Koncki, Z.
    Sumner, P.
    Dumont, N.
    Garcia, G.
    Bloom, T.
    Janovsky, J.
    Reynolds, J.
    Campbell, K.
    Moyo, V.
    Molnar, I.
    LoRusso, P.
    Krop, I.
    Miller, K.
    Ma, C.
    Munster, P.
    Wickham, T.
    CANCER RESEARCH, 2017, 77
12345